Innovative drug treatment regimen helps bone marrow transplant patients get rid of cGVHD. (cGVHD) often goes through three stages, and more than half of patients are already at moderate to severe levels when they arrive at the hospital for diagnosis.
Traditional anti-rejection drugs mainly target the skin, but for fibrosis, especially pulmonary fibrosis,. the clinical effectiveness is even less than 10%. Patients are in urgent need of innovative treatment options. In August 2023, immunomodulators that can target ROCK2 were approved in China for the treatment of cGFHD patients 12 years old and above who have insufficient response to glucocorticoids.